70 related articles for article (PubMed ID: 15249719)
1. Role of F18-FDG PET for monitoring of radiochemotherapy -- estimation of detectable number of tumour cells.
Ruf J; Amthauer H; Oettle H; Steinmüller T; Plotkin M; Pelzer U; Scholman HJ; Felix R; Wust P
Onkologie; 2004 Jun; 27(3):287-90. PubMed ID: 15249719
[TBL] [Abstract][Full Text] [Related]
2. FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer.
Kitagawa Y; Sano K; Nishizawa S; Nakamura M; Ogasawara T; Sadato N; Yonekura Y
Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):63-71. PubMed ID: 12483411
[TBL] [Abstract][Full Text] [Related]
3. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.
Bang S; Chung HW; Park SW; Chung JB; Yun M; Lee JD; Song SY
J Clin Gastroenterol; 2006; 40(10):923-9. PubMed ID: 17063113
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) --usefulness and limitations in "clinical reality".
Higashi T; Saga T; Nakamoto Y; Ishimori T; Fujimoto K; Doi R; Imamura M; Konishi J
Ann Nucl Med; 2003 Jun; 17(4):261-79. PubMed ID: 12932109
[TBL] [Abstract][Full Text] [Related]
5. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
[TBL] [Abstract][Full Text] [Related]
6. [[18F]-FDG-PET in the diagnostics of gastrointestinal tumors].
Buchmann I; Ganten TM; Haberkorn U
Z Gastroenterol; 2008 Apr; 46(4):367-75. PubMed ID: 18393156
[TBL] [Abstract][Full Text] [Related]
7. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
8. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
[TBL] [Abstract][Full Text] [Related]
9. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
10. [18 F-fluorodeoxyglucose positron emission tomography for characterization and initial staging of pancreatic tumors].
Valinas R; Barrier A; Montravers F; Houry S; Talbot JN; Huguier M
Gastroenterol Clin Biol; 2002 Oct; 26(10):888-92. PubMed ID: 12434099
[TBL] [Abstract][Full Text] [Related]
11. FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study.
Maisey NR; Webb A; Flux GD; Padhani A; Cunningham DC; Ott RJ; Norman A
Br J Cancer; 2000 Aug; 83(3):287-93. PubMed ID: 10917540
[TBL] [Abstract][Full Text] [Related]
12. Retrospective digital image fusion of multidetector CT and 18F-FDG PET: clinical value in pancreatic lesions--a prospective study with 104 patients.
Lemke AJ; Niehues SM; Hosten N; Amthauer H; Boehmig M; Stroszczynski C; Rohlfing T; Rosewicz S; Felix R
J Nucl Med; 2004 Aug; 45(8):1279-86. PubMed ID: 15299049
[TBL] [Abstract][Full Text] [Related]
13. Clinical role of (18)F-FDG PET for initial staging of patients with extrahepatic bile duct cancer.
Kato T; Tsukamoto E; Kuge Y; Katoh C; Nambu T; Nobuta A; Kondo S; Asaka M; Tamaki N
Eur J Nucl Med Mol Imaging; 2002 Aug; 29(8):1047-54. PubMed ID: 12173019
[TBL] [Abstract][Full Text] [Related]
14. [Positron emission tomography for the preoperative staging of esophageal carcinoma].
Junginger T; Kneist W; Schreckenberger M; Menzel C; Oberholzer K; Bartenstein P
Dtsch Med Wochenschr; 2002 Sep; 127(38):1935-41. PubMed ID: 12239652
[TBL] [Abstract][Full Text] [Related]
15. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
[TBL] [Abstract][Full Text] [Related]
16. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation.
Anderson GS; Brinkmann F; Soulen MC; Alavi A; Zhuang H
Clin Nucl Med; 2003 Mar; 28(3):192-7. PubMed ID: 12592125
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis of pancreatic carcinoma: role of FDG PET.
Keogan MT; Tyler D; Clark L; Branch MS; McDermott VG; DeLong DM; Coleman RE
AJR Am J Roentgenol; 1998 Dec; 171(6):1565-70. PubMed ID: 9843289
[TBL] [Abstract][Full Text] [Related]
18. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.
Kostakoglu L; Leonard JP; Kuji I; Coleman M; Vallabhajosula S; Goldsmith SJ
Cancer; 2002 Feb; 94(4):879-88. PubMed ID: 11920454
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of intraoperative radiation therapy for unresectable pancreatic cancer with FDG PET.
Higashi T; Sakahara H; Torizuka T; Nakamoto Y; Kanamori S; Hiraoka M; Imamura M; Nishimura Y; Tamaki N; Konishi J
J Nucl Med; 1999 Sep; 40(9):1424-33. PubMed ID: 10492360
[TBL] [Abstract][Full Text] [Related]
20. Role of positron emission tomography with 2-deoxy-2-[18F]fluoro-D-glucose in evaluating the effects of arterial infusion chemotherapy and radiotherapy on pancreatic cancer.
Yoshioka M; Sato T; Furuya T; Shibata S; Andoh H; Asanuma Y; Hatazawa J; Shimosegawa E; Koyama K; Yamamoto Y
J Gastroenterol; 2004 Jan; 39(1):50-5. PubMed ID: 14767734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
